Commercial ViabilityLittle to none. NASA will have to heavily subsidise the work and it's applicable to astronauts and the lucky few for recreational space travel.
The US patent doesn't cover Spaceflight Associated Neuro-ocular Syndrome (SANS), but given the mechanism is similar to reducing intracranial pressure, the only GLP-1 that will have data and regulatory approval will be Presendin.
The benefit to Invex
Hopefully the company provides some guidance to the ASX if this is material.
The FDA have a close relationship with NASA in terms of a MOU, but yet have rarely used data from microgravity to support the efficacy of a drug in a New Drug Application(NDA).
In order to attract a premium valuation from Big Pharma, we need to show a pipeline of possible future indications for Presendin - so sponsored research for Presendin in SANS builds out the pipeline and de-risks its mechanism of reducing intracranial pressure.
- Forums
- ASX - By Stock
- IXC
- Invex in Space?
Invex in Space?, page-10
-
-
- There are more pages in this discussion • 28 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IXC (ASX) to my watchlist
(20min delay)
|
|||||
Last
8.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.463M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 125000 | 8.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.8¢ | 5755 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 125000 | 0.082 |
1 | 84879 | 0.076 |
1 | 6693 | 0.075 |
1 | 500000 | 0.040 |
1 | 70001 | 0.036 |
Price($) | Vol. | No. |
---|---|---|
0.088 | 5755 | 1 |
0.095 | 100000 | 1 |
0.100 | 2750 | 1 |
0.150 | 713 | 1 |
0.000 | 0 | 0 |
Last trade - 16.12pm 15/10/2024 (20 minute delay) ? |
Featured News
IXC (ASX) Chart |
Day chart unavailable
The Watchlist
JBY
JAMES BAY MINERALS LIMITED
Andrew Dornan, Executive Director
Andrew Dornan
Executive Director
SPONSORED BY The Market Online